Benzgalantamine

Benzgalantamine, sold under the brand name Zunveyl, is a medication used for the treatment of mild to moderate dementia of the Alzheimer's type.^[1] It is a cholinesterase inhibitor.^[1] Benzgalantamine is a prodrug of galantamine.^[1]

Benzgalantamine

Clinical data
Trade names	Zunveyl
Other names	ALPHA-1062
AHFS/Drugs.com	Zunveyl
License data	US DailyMed: Benzgalantamine
Routes of administration	By mouth
Drug class	Cholinesterase inhibitor
ATC code	None
Legal status
Legal status	US: ℞-only[1]
Identifiers
CAS Number	224169-27-1 1542321-58-3
DrugBank	DB19353
UNII	XOI2Q0ZF7G LN7PMJ4P57
KEGG	D12930 D12931
ChEMBL	ChEMBL5095056
Chemical and physical data
Formula	C24H25NO4
Molar mass	391.467 g·mol−1
3D model (JSmol)	Interactive image
SMILES COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2
InChI InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1 Key:JKVNJTYHRABHIY-WXVUKLJWSA-N

The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.^[1]

Benzgalantamine was approved for medical use in the United States in July 2024.^[1][2][3]

Medical uses

Benzgalantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.^[1][2]

Side effects

The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.^[1]

Society and culture

Legal status

Benzgalantamine was approved for medical use in the United States in July 2024.^[1][2]

Names

Benzgalantamine is the international nonproprietary name.^[4]